Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
China · Delayed Price · Currency is CNY 82.15
+4.46 (5.74%)
At close: Mar 6, 2026
SHA:688266 Revenue
In the year 2025, Suzhou Zelgen Biopharmaceuticals had annual revenue of 812.73M CNY with 52.50% growth. Suzhou Zelgen Biopharmaceuticals had revenue of 219.29M in the quarter ending December 31, 2025, with 47.34% growth.
Revenue
812.73M
Revenue Growth
+52.50%
P/S Ratio
26.76
Revenue / Employee
893.11K
Employees
910
Market Cap
21.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 812.73M | 279.78M | 52.50% |
| Dec 31, 2024 | 532.95M | 146.52M | 37.91% |
| Dec 31, 2023 | 386.44M | 84.13M | 27.83% |
| Dec 31, 2022 | 302.31M | 111.94M | 58.81% |
| Dec 31, 2021 | 190.36M | 162.70M | 588.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DaShenLin Pharmaceutical Group | 26.83B |
| Yili Chuanning Biotechnology | 4.74B |
| Hualan Biological Engineering | 4.27B |
| Xiamen Amoytop Biotech | 3.70B |
| Anhui Anke Biotechnology (Group) | 2.58B |
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Sinocelltech Group | 1.56B |